2. Others Cell Cycle/DNA Damage Apoptosis
  3. Drug Isomer CDK Apoptosis DNA/RNA Synthesis
  4. Enitociclib

Enitociclib  (Synonyms: (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib)

Cat. No.: HY-103019 Purity: 99.89%
COA
SDS
Handling Instructions Technical Support

Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma.

For research use only. We do not sell to patients.

Enitociclib

Enitociclib Chemical Structure

CAS No. : 1610408-97-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
2 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Enitociclib:

Enitociclib Related Antibodies

Top Publications Citing Use of Products

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma[1][2][3][4].
IC50 & Target

RNA Polymerase

 

CDK9/CycT1

3 nM (IC50)

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
52 nM
Compound: 32
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
[PMID: 34264057]
MOLM-13 IC50
29 nM
Compound: 13; VIP152
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 38564299]
MOLM-13 IC50
42 nM
Compound: 32
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
[PMID: 34264057]
In Vitro

Enitociclib effectively reduces the viability of a panel of human lymphoma cell lines, including the DLBCL cell lines SU-DHL-4 (IC50=43 nmol/L) and SU-DHL-10 (IC50=74 nmol/L)[1].
Enitociclib (0.25-1 μM; 4 h) induces transcriptomic changes dominated by significant downregulation in SU-DHL-4 and SU-DHL-10 DLBCL cell lines, including marked downregulation of novel targets PHF23 and TP53RK, as well as enrichment of the RNA polymerase II-mediated transcription pathway[1].
Enitociclib (0.6-800 nM; 6-48 h) potently inhibits the viability of primary mantle cell lymphoma (MCL) cells, MCL cell lines, and diffuse large B-cell lymphoma (DLBCL) cell lines, and induces caspase-3-dependent apoptosis in these cells, with an IC50 of 11.5-172.3 nM[2].
Enitociclib (12.5-200 nM; 96 h) significantly reduces the cell viability of multiple myeloma cell lines MM1.S, NCI-H929, OPM-2 and U266B1, with an IC50 ranging from 36 to 78 nM after 96 hours of treatment[3].
Enitociclib (0.5-1 μM; 1-24 h) inhibits phosphorylation of RNA Pol II CTD at Ser2/Ser5 sites in a dose- and time-dependent manner, induces apoptosis, and suppresses oncoprotein expression in NCI-H929 and OPM-2 multiple myeloma cell lines[3].
Enitociclib (25-500 nM; combined with paclitaxel) synergistically inhibits the growth of paclitaxel-resistant L3.6pl pancreatic cancer cells[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Enitociclib Related Antibodies

Western Blot Analysis[1]

Cell Line: SU-DHL-4, SU-DHL-10 (DLBCL) cell lines
Concentration: 0.25 μmol/L; 1 μmol/L
Incubation Time: 4 h (treatment); up to 48 h post-washout (SU-DHL-4); up to 24 h post-washout (SU-DHL-10)
Result: Decreased p-Ser2 levels by 50% for up to 48 hours post-washout in SU-DHL-4 cells treated with 0.25 μmol/L.
Caused a greater extent of p-Ser2 inhibition that sustained for 48 hours post-washout in SU-DHL-4 cells treated with 1 μmol/L.
Achieved a 50% reduction of p-Ser2 for up to 24 hours post-washout in SU-DHL-10 cells treated with 1 μmol/L.

Real Time qPCR[1]

Cell Line: SU-DHL-4, SU-DHL-10 (DLBCL) cell lines
Concentration: 0.25 μmol/L; 1 μmol/L
Incubation Time: 4 h (treatment); up to 48 h post-washout
Result: Inhibited MYC and MCL1 mRNA levels by approximately 75% for 16 to 48 hours post-washout in SU-DHL-10 cells.
Maintained durable depletion of MYC and MCL1 mRNA levels over the 48-hour time course in SU-DHL-4 cells treated with 1 μmol/L.

Cell Viability Assay[3]

Cell Line: MM1.S, NCI-H929, OPM-2, U266B1 multiple myeloma cell lines
Concentration: 12.5-50 nM (in combination with other agents)
Incubation Time: 96 h
Result: Exhibited synergistic effects (ZIP synergy score >10) with bortezomib in OPM-2 cells at 50 nM enitociclib and 1 nM bortezomib.
Showed synergistic effects with lenalidomide in MM1.S, NCI-H929, and U266B1 cells at 12.5 to 25 nM enitociclib and 313 nM to 5 μM lenalidomide.
Demonstrated synergistic effects with pomalidomide in NCI-H929 and U266B1 cells at 12.5 nM enitociclib and 12.5 to 50 nM pomalidomide.
In Vivo

Enitociclib (5-15 mg/kg; i.v.; single dose/once weekly; 3 weeks) exerts dose-dependent antitumor efficacy in SU-DHL-10 DLBCL xenografts, with 15 mg/kg once weekly dosing inducing complete tumor regression, and all tested doses driving pharmacodynamic effects including reduced p-Ser2, depleted MYC/MCL1 expression, and activated apoptosis[1].
Enitociclib (10 mg/kg; i.v.; twice a week) potently inhibits tumor growth and prolongs survival in JeKo-1 MCL cell line-derived xenografts in NSG mice (p < 0.0001 for both endpoints) without significant toxicity[2].
Enitociclib (15 mg/kg; i.v.; once per week) significantly reduces JJN-3 multiple myeloma tumor volumes in SCID/Beige mice, and a single dose (15 mg/kg; i.v.) transiently suppresses oncogene transcription and induces tumor apoptosis[3].
Enitociclib (15 mg/kg; i.v.; once per week) significantly reduces OPM-2 multiple myeloma tumor volumes in NOD/SCID mice, and enhances efficacy when combined with lenalidomide or bortezomib[3].
Enitociclib (10 mg/kg; i.v.; once weekly; 4 weeks) does not reduce tumor size as a single agent, but in combination with paclitaxel, it induces significant tumor shrinkage in a paclitaxel-resistant PDAC patient-derived xenograft model[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C.B-17 SCID (female, 10-12 weeks old at study start)[1]
Dosage: 5 mg/kg (mechanistic single dose); 10 mg/kg (i.v. once weekly for 3 weeks; mechanistic single dose); 15 mg/kg (i.v. once weekly for 3 weeks; mechanistic single dose)
Administration: i.v.; single dose (mechanistic studies); once weekly; 3 weeks (antitumor efficacy)
Result: Achieved a tumor growth inhibition (T/C) value of 0.19 on day 16/20, with sustained tumor growth control at 10 mg/kg once weekly.
Induced complete tumor regression during the 3-week treatment period, with a T/C value of 0.005 on day 16/20 at 15 mg/kg once weekly; tumors regrew after treatment cessation, but a second cycle of 15 mg/kg once weekly dosing induced tumor regression again.
Reduced RNA polymerase II Ser2 phosphorylation (p-Ser2) by >50% for 8 hours postdose; depleted MYC and MCL1 mRNA levels by 4 hours postdose, with depletion sustained for 8 hours at 5 mg/kg single dose.
Depleted p-Ser2 levels within 8 hours postdose; depleted MYC and MCL1 mRNA levels by 4 hours postdose, with depletion sustained for 8 hours; reduced Myc protein levels by 50% and Mcl-1 protein levels robustly within 4-8 hours postdose; increased cleaved PARP (apoptosis marker) levels postdose at 10 mg/kg and 15 mg/kg single dose.
Animal Model: NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (immunodeficient)[2]
Dosage: 10 mg/kg
Administration: i.v.; twice a week
Result: Markedly inhibited tumor growth.
Significantly prolonged mouse survival.
Caused no significant body weight loss or other apparent adverse effects.\nEfficaciously inhibited PDX-1 tumor growth.
Caused no significant body weight loss.\nEfficaciously inhibited PDX-2 tumor growth.
Caused no significant body weight loss.\nEfficaciously inhibited PDX-3 tumor growth.
Caused no significant body weight loss.
Animal Model: NOD/SCID (gender not specified; injected subcutaneously with 5.0×106 OPM-2 MM cells)[3]
Dosage: 15 mg/kg (monotherapy); 15 mg/kg (in combination with lenalidomide or bortezomib)
Administration: i.v.; once per week
Result: Significantly reduced OPM-2 tumor volumes compared with vehicle-treated mice as monotherapy.
Further enhanced antitumor efficacy compared with lenalidomide or bortezomib alone when combined with 50 mg/kg Lenalidomide (p.o.
daily) or 0.8 mg/kg Bortezomib (i.p.
twice weekly).
Molecular Weight

404.43

Formula

C19H18F2N4O2S
CAS No.
Appearance

Solid

Color

Off-white to yellow

SMILES

COC1=C(C2=C(F)C=NC(NC3=CC(C[S@@](=O)(C)=N)=CC=N3)=C2)C=CC(F)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 113.3 mg/mL (280.15 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4726 mL 12.3631 mL 24.7262 mL
5 mM 0.4945 mL 2.4726 mL 4.9452 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.89%

SDS (254 KB)

COA (247 KB) HNMR (380 KB) LCMS (91 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.4726 mL 12.3631 mL 24.7262 mL 61.8154 mL
5 mM 0.4945 mL 2.4726 mL 4.9452 mL 12.3631 mL
10 mM 0.2473 mL 1.2363 mL 2.4726 mL 6.1815 mL
15 mM 0.1648 mL 0.8242 mL 1.6484 mL 4.1210 mL
20 mM 0.1236 mL 0.6182 mL 1.2363 mL 3.0908 mL
25 mM 0.0989 mL 0.4945 mL 0.9890 mL 2.4726 mL
30 mM 0.0824 mL 0.4121 mL 0.8242 mL 2.0605 mL
40 mM 0.0618 mL 0.3091 mL 0.6182 mL 1.5454 mL
50 mM 0.0495 mL 0.2473 mL 0.4945 mL 1.2363 mL
60 mM 0.0412 mL 0.2061 mL 0.4121 mL 1.0303 mL
80 mM 0.0309 mL 0.1545 mL 0.3091 mL 0.7727 mL
100 mM 0.0247 mL 0.1236 mL 0.2473 mL 0.6182 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Enitociclib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Enitociclib1610408-97-3(+)-BAY-1251152 (+)-VIP152 (S)-EnitociclibDrug IsomerCDKApoptosisDNA/RNA SynthesisCyclin dependent kinasemultiple myelomamantle cell lymphomaMCL-1MYC-positive non-Hodgkin lymphomacaspase-3double-hit diffuse large B-cell lymphomaCDK9c-MYCRNA polymerase IIcyclin-dependent kinase 9Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Enitociclib
Cat. No.:
HY-103019
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.